Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SEC
SEC
Cassava Sciences: Phase III trials storm ahead amid controversy
Clinical Trials Arena
Wed, 10/9/24 - 09:56 am
Cassave Sciences
clinical trials
simufilam
SEC
Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
Fierce Biotech
Mon, 09/30/24 - 09:23 am
Cassava Sciences
Alzheimer's disease
SEC
SEC Hits Allarity With Wells Notice, Flags Alleged Violations in FDA Meeting
BioSpace
Tue, 07/23/24 - 11:32 am
Allarity Therapeutics
SEC
FDA
securities law
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy
BioSpace
Fri, 04/5/24 - 11:52 am
Novo Nordisk
M&A
Catalent
SEC
BioMarin Hit with DOJ Subpoena on Sponsored Testing for Rare Diseases
BioSpace
Tue, 02/27/24 - 11:31 am
Biomarin
SEC
DOJ
Vimizim
Naglazyme
Catalent delays quarterly filing with SEC on $700 mln impairment charge
Reuters
Tue, 11/14/23 - 11:18 am
Catalent
SEC
M&A
SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL
BioSpace
Fri, 08/11/23 - 11:40 am
SEC
Illumina
Grail
M&A
cancer
diagnostics
Former Merck VP Nirdosh Jagota settles with SEC on insider trading charge
Fierce Pharma
Thu, 07/20/23 - 09:58 am
Merck
Pandion Therapeutics
SEC
insider trading
BioXCell’s potential episodic Alzheimer’s agitation treatment marred by missed trial protocols, fabricated emails and failed endpoint
Fierce Pharma
Thu, 06/29/23 - 11:42 am
BioXCell
Alzheimer's disease
Alzheimer's agitation
dexmedetomidine
SEC
Philips will pay more than $62M to settle SEC corruption charges
Medtech Dive
Fri, 05/12/23 - 11:32 am
Philips
Medtech
SEC
FCPA
China
legal
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Fierce Pharma
Tue, 03/28/23 - 10:57 pm
Esperion Therapeutics
Daiichi Sankyo
Nexletol
SEC
SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance
Endpoints
Thu, 03/16/23 - 07:00 pm
Eli Lilly
SEC
abortion
diversity
DEI
Indiana
Viatris executive charged in insider trading scheme that allegedly netted $7.2 million
Fierce Pharma
Sun, 11/13/22 - 06:55 pm
Viatris
insider trading
SEC
Zymergen Cuts 80 More Jobs, Parts Ways with Co-Founder
BioSpace
Fri, 08/26/22 - 10:39 am
Zymergen
SEC
layoffs
AbbVie calls off PhI trial for I-Mab’s CD47 days after Zai Lab shelves its own program
Endpoints
Tue, 08/16/22 - 11:59 pm
AbbVie
CD47
SEC
clinical trials
I-Mab
Zai Lab
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless
Endpoints
Thu, 07/21/22 - 09:47 pm
Biogen
Aduhelm
Alzheimer's disease
SEC
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Fierce Pharma
Wed, 07/13/22 - 10:09 am
Epizyme
SEC
M&A
Ipsen
How Pfizer CEO Bourla's evening call brought Biohaven back into the M&A fold
Fierce Pharma
Wed, 07/6/22 - 11:01 am
Pfizer
Pfizer CEOs
Albert Bourla
M&A
Biohaven
SEC
Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges
Endpoints
Tue, 05/31/22 - 10:39 am
AstraZeneca
insider trading
SEC
Enhertu
Daiichi Sankyo
In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports
Endpoints
Thu, 05/5/22 - 11:34 pm
Biogen
earnings
SEC
Eli Lilly
Merck
Bristol Myers Squibb
Pfizer
AbbVie
Pages
1
2
3
4
5
6
7
8
next ›
last »